Table 13, Hospitalization for Any Cause During GRIPHON - Clinical Review Report: Slexipag (Uptravi)

	Selexipag N = 574	Placebo N = 582
PAH-related hospitalizations up to end-of-study visit	▬	▬
Number of hospitalizations for all causes up to end-of-study visit	▬	▬
Cumulative time on study	▬	▬
Group level annualized number of hospitalizations/year	▬	▬
Total number of days spent in hospital	▬	▬
Group level annualized number of days spent in hospital/year	▬	▬

Cover of Clinical Review Report: Slexipag (Uptravi)

Clinical Review Report: Slexipag (Uptravi) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 13Hospitalization for Any Cause During GRIPHON